Myocardial Infarction (MI)DaZiRNCT07835282
Germany on Target Registry
An observational study of Myocardial Infarction (MI) and Dyslipidemias, run by Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga.
Trial summary
Germany on Target Registry (DaZiR) is a prospective, Germany-wide patient registry designed to assess lipid management and low-density lipoprotein cholesterol ( LDL-C) target attainment in adults following acute myocardial infarction (STEMI or NSTEMI). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Infarction (MI), Dyslipidemias
- What is being tested?
- No study-assigned intervention
- How many people
- 10,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2026to 31 Dec 2050
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults aged 18 years or older following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) treated in Germany. Potential participants are identified and informed about the registry by physicians or medical institutions and voluntarily enroll using an individual access link or QR code.
Who may be able to join
- Age ≥18 years
- Diagnosis of acute ST-elevation myocardial infarction (STEMI) or non-ST- elevation myocardial infarction (NSTEMI)
- Provision of informed consent for participation in the registry
Who cannot join
- No informed consent for participation in the registry
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Germany on Target Registry (DaZiR) is a prospective, Germany-wide patient registry designed to assess lipid management and low-density lipoprotein cholesterol ( LDL-C) target attainment in adults following acute myocardial infarction (STEMI or NSTEMI).
Eligible patients are informed about the registry by treating physicians or their medical teams and receive an individual access link or QR code. Following electronic informed consent and registration, participants provide clinical and follow-up information through the brite™ platform.
Read more
Clinical data, including LDL-C values and lipid-lowering treatment, can be entered by the participants or obtained from uploaded medical documents. The platform enables participants to follow the course of their LDL-C values and provides reminders for scheduled follow-up data collection.
Medical treatment is determined independently by the treating physicians as part of routine clinical care and is not assigned by the registry. The registry aims to assess LDL-C target attainment over time, changes in lipid-lowering treatment, treatment adherence and cardiovascular outcomes following myocardial infarction.
Read the detailed description
Germany on Target Registry is a prospective patient registry investigating lipid management and cardiovascular secondary prevention following acute myocardial infarction in Germany.
Adults following ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) may be informed about the registry by participating physicians and medical institutions. The role of the physicians is primarily limited to identifying potentially eligible patients, providing information about the registry and supplying an individual access link or QR code.
Following registration and electronic informed consent, further study participation is conducted through the Brite™ digital platform provided by XO Life. Participants provide follow-up information directly through the platform. Relevant laboratory values can be entered manually or obtained from medical documents uploaded by the participant.
Baseline information includes characteristics of the index myocardial infarction, LDL-C values at admission and/or discharge, lipid-lowering treatment and relevant cardiovascular risk factors and laboratory parameters. Follow-up assessments document LDL-C values, changes in lipid-lowering therapy and additional clinical information.
The primary focus of the registry is the proportion of participants achieving the predefined LDL-C target of <55 mg/dL and the maintenance of LDL-C target attainment during follow-up.
Secondary objectives include characterization of the longitudinal LDL-C course, changes and escalation of lipid-lowering therapy, treatment adherence, reported suspected adverse drug reactions and cardiovascular events during follow-up.
The registry does not prescribe a specific lipid-lowering treatment or modification of treatment. Decisions regarding pharmacological treatment remain the responsibility of the participant's treating physicians and are made according to routine clinical care.
- Conditions
- Myocardial Infarction (MI), Dyslipidemias
- Being tested
- No study-assigned intervention
- Keywords
- LDL Cholesterol, LDL-C, ST-Elevation Myocardial Infarction, STEMI, Non-ST-Elevation Myocardial Infarction, NSTEMI, Lipid-Lowering Therapy, Secondary Prevention, Cardiovascular Disease, Dyslipidemia, Patient Registry, Digital Health
- Medical subject headings
- Myocardial Infarction, Dyslipidemias, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No study-assigned interventionOther
Participants receive medical care according to routine clinical practice. The registry does not prescribe or assign lipid-lowering treatment. Lipid-lowering therapies and subsequent treatment changes are documented as part of the observational data collection.
| Study group | Role | What they receive |
|---|---|---|
| Patients following acute myocardial infarction | Adults following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) who voluntarily enroll in the Deutschland auf Ziel registry and are prospectively followed through the brite™ platform. Receives: Other: No study-assigned intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
LDL-C target attainment
The primary endpoint of the study/registry is the achievement and maintenance of the LDL-C target level recommended by the current ESC/EAS guidelines for high-risk cardiovascular patients during the follow-up period. Assessment is based on documented LDL-C measurements taken at specified time points (after 6 weeks, 3, 6, and 12 months, as well as during the subsequent long-term follow-up).
Measured: 12 months
Secondary outcomes (15)
Absolute change in LDL cholesterol
Absolute change in LDL cholesterol concentration from the baseline or discharge value to the predefined follow-up assessments.
Unit: mg/dL
Measured: Baseline to 60 month
Percentage change in LDL cholesterol
Percentage change in LDL cholesterol concentration from the baseline or discharge value to the predefined follow-up assessments.
Unit: %
Measured: Baseline to 60 Month
Body weight
Body weight documented for registry participants. Unit: kg
Measured: Baseline
Body height
Body height documented for registry participants. Unit: cm
Measured: Baseline
Body mass index
Body mass index calculated from documented body weight and height. Unit: kg/m²
Measured: Baseline
HDL cholesterol concentration
High-density lipoprotein cholesterol (HDL) cholesterol concentration documented during registry follow-up.
Unit: mg/dL
Measured: Baseline to 60 month
Triglyceride concentration
Triglyceride concentration documented during registry follow-up.
Measured: Baseline to 60 mionth
Lipoprotein(a) concentration
Lipoprotein(a) concentration documented during registry follow-up. Unit: nmol/L or mg/dL
Measured: Baseline
HbA1c
Glycated hemoglobin (HbA1c) value documented during registry follow-up. Unit: %
Measured: Baseline to 60 month
hsCRP
High-sensitivity C-reactive protein (hsCRP) concentration documented during registry follow-up.
Unit: mg/L
Measured: Baseline to 60 month
Blood pressure
Systolic and diastolic blood pressure documented during registry follow-up. Unit: mmHg
Measured: Baseline
Changes in lipid-lowering therapy during follow-up
Proportion of participants with a documented change in lipid-lowering therapy during follow-up, including initiation, discontinuation, substitution, or modification of lipid-lowering medication.
Measured: Baseline to 60 month
Proportion of participants with documented intensification of lipid-lowering therapy
Proportion of participants with documented intensification of lipid-lowering therapy during follow-up.
Measured: Baseline to 60 month
Participant-reported adherence to prescribed lipid-lowering therapy
Participant-reported adherence to prescribed lipid-lowering therapy during registry follow-up.
Measured: Baseline to 60 month
Occurrence of cardiovascular events during follow-up
Proportion of participants experiencing at least one cardiovascular event during registry follow-up. Cardiovascular events are defined as recurrent ST-elevation myocardial infarction (STEMI), recurrent non-ST-elevation myocardial infarction (NSTEMI), ischemic stroke, or unplanned coronary revascularization.
Measured: Baseline to 60 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2026
- Study start1 Dec 2026 (estimated)
- Primary completion1 Jan 2036 (estimated)
- Study completion31 Dec 2050 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial Infarction (MI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07835282
- Sponsor's protocol ID
- DaZiR-001
- Acronym
- DaZiR
- Status last verified
- Sep 2026
- First submitted
- 10 Sep 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Germany on Target Registry
- ClinicalTrials.gov ID
- NCT07835282
- Acronym / sponsor ID
- DaZiR / DaZiR-001
- Conditions
- Myocardial Infarction (MI), Dyslipidemias
- Keywords
- LDL Cholesterol, LDL-C, ST-Elevation Myocardial Infarction, STEMI, Non-ST-Elevation Myocardial Infarction, NSTEMI, Lipid-Lowering Therapy, Secondary Prevention
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-LigaUniversity, hospital or other
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 1 Jan 2036 (estimated)
- Study completion
- 31 Dec 2050 (estimated)
- First posted
- 22 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Germany on Target Registry (DaZiR) is a prospective, Germany-wide patient registry designed to assess lipid management and low-density lipoprotein cholesterol ( LDL-C) target attainment in adults following acute myocardial infarction (STEMI or NSTEMI).
Eligible patients are informed about the registry by treating physicians or their medical teams and receive an individual access link or QR code. Following electronic informed consent and registration, participants provide clinical and follow-up information through the brite™ platform.
Clinical data, including LDL-C values and lipid-lowering treatment, can be entered by the participants or obtained from uploaded medical documents. The platform enables participants to follow the course of their LDL-C values and provides reminders for scheduled follow-up data collection.
Medical treatment is determined independently by the treating physicians as part of routine clinical care and is not assigned by the registry. The registry aims to assess LDL-C target attainment over time, changes in lipid-lowering treatment, treatment adherence and cardiovascular outcomes following myocardial infarction.
Detailed description
Germany on Target Registry is a prospective patient registry investigating lipid management and cardiovascular secondary prevention following acute myocardial infarction in Germany.
Adults following ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) may be informed about the registry by participating physicians and medical institutions. The role of the physicians is primarily limited to identifying potentially eligible patients, providing information about the registry and supplying an individual access link or QR code.
Following registration and electronic informed consent, further study participation is conducted through the Brite™ digital platform provided by XO Life. Participants provide follow-up information directly through the platform. Relevant laboratory values can be entered manually or obtained from medical documents uploaded by the participant.
Baseline information includes characteristics of the index myocardial infarction, LDL-C values at admission and/or discharge, lipid-lowering treatment and relevant cardiovascular risk factors and laboratory parameters. Follow-up assessments document LDL-C values, changes in lipid-lowering therapy and additional clinical information.
The primary focus of the registry is the proportion of participants achieving the predefined LDL-C target of <55 mg/dL and the maintenance of LDL-C target attainment during follow-up.
Secondary objectives include characterization of the longitudinal LDL-C course, changes and escalation of lipid-lowering therapy, treatment adherence, reported suspected adverse drug reactions and cardiovascular events during follow-up.
The registry does not prescribe a specific lipid-lowering treatment or modification of treatment. Decisions regarding pharmacological treatment remain the responsibility of the participant's treating physicians and are made according to routine clinical care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients following acute myocardial infarction | – | Other: No study-assigned interventionAdults following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) who voluntarily enroll in the Deutschland auf Ziel registry and are prospectively followed through the brite™ platform. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 18 years or older following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) treated in Germany. Potential participants are identified and informed about the registry by physicians or medical institutions and voluntarily enroll using an individual access link or QR code.
Key inclusion criteria (3 listed)
- Age ≥18 years
- Diagnosis of acute ST-elevation myocardial infarction (STEMI) or non-ST- elevation myocardial infarction (NSTEMI)
- Provision of informed consent for participation in the registry
Key exclusion criteria (1 listed)
- No informed consent for participation in the registry
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No study-assigned interventionParticipants receive medical care according to routine clinical practice. The registry does not prescribe or assign lipid-lowering treatment. Lipid-lowering therapies and subsequent treatment changes are documented as part of the observational data collection. | Other | Patients following acute myocardial infarction |
Primary outcome
LDL-C target attainment
Time frame: 12 months
The primary endpoint of the study/registry is the achievement and maintenance of the LDL-C target level recommended by the current ESC/EAS guidelines for high-risk cardiovascular patients during the follow-up period. Assessment is based on documented LDL-C measurements taken at specified time points (after 6 weeks, 3, 6, and 12 months, as well as during the subsequent long-term follow-up).
15 secondary outcomes
Absolute change in LDL cholesterol
Time frame: Baseline to 60 month
Percentage change in LDL cholesterol
Time frame: Baseline to 60 Month
Body weight
Time frame: Baseline
Body height
Time frame: Baseline
Body mass index
Time frame: Baseline
HDL cholesterol concentration
Time frame: Baseline to 60 month
Triglyceride concentration
Time frame: Baseline to 60 mionth
Lipoprotein(a) concentration
Time frame: Baseline
HbA1c
Time frame: Baseline to 60 month
hsCRP
Time frame: Baseline to 60 month
Blood pressure
Time frame: Baseline
Changes in lipid-lowering therapy during follow-up
Time frame: Baseline to 60 month
Proportion of participants with documented intensification of lipid-lowering therapy
Time frame: Baseline to 60 month
Participant-reported adherence to prescribed lipid-lowering therapy
Time frame: Baseline to 60 month
Occurrence of cardiovascular events during follow-up
Time frame: Baseline to 60 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Myocardial Infarction (MI)
Recruiting
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
Myocardial Infarction (MI)
Not yet recruiting
Pilot Study to Determine the Optimal Protocol for Preoperative Transcutaneous Vagal Neurostimulation
Atrial Fibrillation (AF), Cerebral Vascular Accident (CVA)
Active, not recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
Acute Myocardial Infarction, Coronary Artery Disease
Not yet recruitingObservational study
AI-ECG Detection of Occlusion Myocardial Infarction at Emergency Department Triage (TRIACS)
Acute Coronary Syndromes, Chest Pain
Active, not recruitingObservational study
Lipid Testing After Myocardial Infarction at the Montreal Heart Institute
Dyslipidemias, Lipid Testing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Infarction (MI) and Dyslipidemias, run by Deutsche Gesellschaft für Lipidologie e. V. (DGFL) - Lipid-Liga.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Oliver Weingärtner, Prof. Dr. med. (+493641-932-4521, oliver.weingaertner@med.uni-jena.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LDL-C target attainment (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.